Talk:SARS-CoV-2 Delta variant

This article was the subject of a Wiki Education Foundation-supported course assignment, between 23 August 2021 and 10 December 2021. Further details are available on the course page. Student editor(s): Aweger (article contribs).

Incomplete sentence?

The sentence "These fatality rates are lower than the average fatality rate of 1.9%, presumably due to the now relative high percentage of the more vulnerable in England." seems incomplete. Is something like "... that have been vaccinated." missing at the end?

study https://www.medrxiv.org/content/10.1101/2021.08.08.21261768v1.article-metrics

When it says "On August 10, a study showed that the full vaccination coverage rate is correlated inversely to the SARS-CoV-2 delta variant mutation frequency in 16 countries (R-squared=0.878). Data strongly indicates that full vaccination against COVID-19 is critical to suppress emergent mutations.[68]"

This study is a PREPRINT and the statistic analysis isn't rigorous because it violates some assumptions and it has some issues not addressed by the researcher.

Merge into SARS-CoV-2 page

I don't believe this should be it's own page, a lot of the information on here is redundant and could better be explained by being a subunit of the SARS-COV-2 page Reeeweee (talk) 04:26, 28 December 2021 (UTC)

Semi-protected edit request on 13 January 2022

Change: Most U.S. doctors have no way to determine which variant of the coronavirus a patient is carrying, a distinction that could mean the difference between life and death. High-risk patients carrying the Delta variant could benefit greatly from two particular monoclonal antibody treatments shown to reduce hospitalization and death. But those medications would most likely do nothing for patients with Omicron, who would only respond to a third antibody treatment that is in very short supply. Differentiation of Delta and Omicron variants is also crucial in the decision making of high risk patients, especially when deciding whether they should be considered for in-patient care versus outpatient follow-up.

Delta patients benefit most from the antibody drugs made by Regeneron (casirivimab and imdevimab) and Eli Lilly (Bamlanivimab), while Omicron patients benefit from antibodies from GlaxoSmithKline and Vir Biotechnology (sotrovimab (VIR-7831)).

An example of a test that can differentiate these variants are seqeuencing and PCR tests such as GG COVID-19 Omicron and Delta kit. Also, the ability to screen tens of thousands of patients per lab in one setting is something that sequencing can never do, but real-time PCR can do, as sequencing is highly labor instensive and even world-class laboratories usually process less than a hundred a week. This is also due to the fact that single PCR has to be done and if the PCR doesn't come out (specimen quality, etc), sequencing cannot be done. However, due to the amplification properties of re-time PCR, GG COVID-19 Omicron and Delta kit is able to detect most covid-19 infections and whetehr it is Delta, Omicron, or neither. It also has the ability detect Stealth Omicron (BA.2) and has the potential to detect future mixed delta and omicron type which may well be a problem in the future.

There needs to be a test that will be able to tell if a newly infected individual with COVID-19 has the Delta variant or the Omicron variant, as the clinician who sees the COVID-19 patient firsthand should be able to triage the COVID-19 patient in regards to disease severity, underlying disease status, and the variant status and for this PCR testing such as GG COVID-19 Omicron and Delta kit has to be introduced as soon as possible. Jjn1983 (talk) 09:03, 13 January 2022 (UTC)

 Not done: it's not clear what changes you want to be made. Please mention the specific changes in a "change X to Y" format and provide a reliable source if appropriate. ScottishFinnishRadish (talk) 10:22, 13 January 2022 (UTC)